A practical reference on peptide research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-22 and is reviewed periodically as new material appears.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== SCIRI === The organization was formed in Iran in 1982 as the military wing of the Supreme Council for Islamic Revolution in Iraq. It was based in Iran for two decades during the rule of Saddam Hussein and led by Iranian officers. It consisted of several thousand Iraqi exiles, refugees, and Iraqi Army defectors who fought alongside Iranian troops in the Iran–Iraq War. The group was armed and directed by Iran. They briefly returned to Iraq in 1991 during the 1991 Iraqi uprising to fight against the government of Saddam Hussein, focusing on the Shia holy cities of Najaf and Karbala. They retreated into Iran after the uprising was brutally crushed by the Ba'athist regime. In 1995, during the Iraqi Kurdish Civil War, Iran deployed 5,000 Badr fighters to Iraqi Kurdistan to support the PUK forces.
What is the strength of the component as a function of crack size? What crack size can be tolerated under service loading, i.e. what is the maximum permissible crack size? How long does it take for a crack to grow from a certain initial size, for example the minimum detectable crack size, to the maximum permissible crack size? What is the service life of a structure when a certain pre-existing flaw size (e.g. a manufacturing defect) is assumed to exist? During the period available for crack detection how often should the structure be inspected for cracks?
== Diagnosis == Diagnosis of fibromyalgia is hampered by the lack of any single pathological feature, laboratory finding, or biomarker. In most cases, people with fibromyalgia symptoms may have laboratory test results that appear normal, and many of their symptoms may mimic those of other rheumatic conditions such as arthritis or osteoporosis. Specific diagnostic criteria for fibromyalgia have evolved.
=== Countercurrent exchange in sea and desert birds to conserve water === Sea and desert birds have been found to have a salt gland near the nostrils which concentrates brine, later to be "sneezed" out to the sea, in effect allowing these birds to drink seawater without the need to find freshwater resources. It also enables the seabirds to remove the excess salt entering the body when eating, swimming or diving in the sea for food. The kidney cannot remove these quantities and concentrations of salt. The salt secreting gland has been found in seabirds like pelicans, petrels, albatrosses, gulls, and terns. It has also been found in Namibian ostriches and other desert birds, where a buildup of salt concentration is due to dehydration and scarcity of drinking water. In seabirds the salt gland is above the beak, leading to a main canal above the beak, and water is blown from two small nostrils on the beak, to empty it. The salt gland has two countercurrent mechanisms working in it: a. A salt extraction system with a countercurrent multiplication mechanism, where salt is actively pumped from the blood 'venules' (small veins) into the gland tubules. Although the fluid in the tubules is with a higher concentration of salt than the blood, the flow is arranged in a countercurrent exchange, so that the blood with a high concentration of salt enters the system close to where the gland tubules exit and connect to the main canal.
Romaine (1806), speaker of the New York State Assembly Egbert Benson (1807), member of the Board of Aldermen of New York City and 4th president of the Saint Nicholas Society of the City of New York, nephew of founding father Egbert Benson Henry H. Ross (1808), U.S. congressman from New York Peter Dumont Vroom (1808), U.S. minister to Prussia and governor of New Jersey John Fine (1809), U.S. congressman from New York John Slidell (1810), Confederate minister to France and a central figure of the Trent Affair during the American Civil War; United States senator from Louisiana, brother-in-law of Admiral Matthew C. Perry Charles G. Ferris (1811), U.S. congressman from New York Van Brugh Livingston (1811), chargé d'affaires to Ecuador Nathanael G. Pendleton (1813), U.S. congressman from Ohio Samuel L. Gouverneur (1817), postmaster of New York City, private secretary, nephew, and son-in-law of President James Monroe James I. Roosevelt (1815), U.S. congressman from New York; brother of Cornelius Roosevelt William Beach Lawrence (1818), U.S. chargé d'affaires for Great Britain and acting governor of Rhode Island William F. Havemeyer (1823), three-time mayor of New York City William Duer (1824), U.S.congressman from New York John McKeon (1825): U.S. attorney, Southern District of New York; U.S. congressman from New York Hamilton Fish (1827), US secretary of state; governor of New York; United States senator from New York John Henry Hobart Haws (1827), U.S. congressman from New York John D.
Sources: en.wikipedia.org
== Further reading == Bachner, Paul (2021). In further pursuit of excellence: the college of American pathologists 1946-2020 (PDF) (1st ed.). Northfield: College of American Pathologists. ISBN 978-1-941096-61-1.
== Dependence and withdrawal == Nonbenzodiazepines are as addictive as benzodiazepines. Nonbenzodiazepines should not be discontinued abruptly if taken for more than a few weeks due to the risk of rebound withdrawal effects and acute withdrawal reactions, which may resemble those seen during benzodiazepine withdrawal. Treatment usually entails gradually reducing the dosage over a period of weeks or several months depending on the individual, dosage, and length of time the drug has been taken. If this approach fails, a crossover to a benzodiazepine equivalent dose of a long-acting benzodiazepine (such as chlordiazepoxide or more preferably diazepam) can be tried followed by a gradual reduction in dosage. In extreme cases and, in particular, where severe addiction and/or abuse is manifested, an inpatient detoxification may be required.<
=== Other formulations === The original oral formulation of selegiline was developed for the treatment of depression. However, it ended up being developed and approved for the treatment of Parkinson's disease instead. In any case, oral selegiline has been widely used off-label to treat depression. The transdermal patch form of selegiline was developed and approved specifically for the treatment of depression. It was also under development for the treatment of Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), cognition disorders, and Parkinson's disease, but development for these indications was discontinued. The ODT form of selegiline was developed and licensed exclusively for the treatment of Parkinson's disease.
=== India === G. N. Singh, India's top drug regulator, said in a 2014 interview: "If I have to follow U.S. standards in inspecting facilities supplying to the Indian market, […] we will have to shut almost all of those." According to Outsourcing Pharma in 2012, 75% of counterfeit drugs supplied worldwide had some origins in India, followed by 7% from Egypt and 6% from China. In 2009, the Central Drug Standards Control Organisation (CDSCO), the drug regulatory authority of India conducted a nationwide survey, and announced that of "24,000 samples [that] were collected from all over India and tested. It was found that only 11 samples or 0.046% were spurious." In 2017 a similar survey found 3.16% of the medicines sampled were substandard and 0.0245% were fake. Those more commonly prescribed are probably more often faked. In 2017, industry body ASSOCHAM wrote in the paper "Fake and Counterfeit Drugs In India –Booming Biz" that fake drugs constitute US$4.25 billion of the total US$14–17 billion of domestic drug market. Around 25% of India's drugs are fake, counterfeit or substandard. If the fake drugs market grows at the current rate of 25%, it will cross the US$10 billion mark by 2017. Trade in fake drugs is driven caused by lack of adequate regulations, shortage of drug inspectors and a lack of lab facilities to check the purity of drugs. Other key factors include storage of spurious drugs by chemists, weaknesses in drug distribution system, lack of awareness among consumers and lack of law enforcement.
=== Electron transfer flavoprotein-Q oxidoreductase === Electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-Q oxidoreductase), also known as electron transferring-flavoprotein dehydrogenase, is a third entry point to the electron transport chain. It is an enzyme that accepts electrons from electron-transferring flavoprotein in the mitochondrial matrix, and uses these electrons to reduce ubiquinone. This enzyme contains a flavin and a [4Fe–4S] cluster, but, unlike the other respiratory complexes, it attaches to the surface of the membrane and does not cross the lipid bilayer.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.